Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with significant revenue and net income growth, a raised revenue guidance for 2025, and strategic product development plans. Despite some uncertainties in global market access and management's vague responses in the Q&A, the overall sentiment is positive due to the raised guidance and strong financial metrics. The market cap suggests a moderate reaction, leading to a predicted stock price movement of 2% to 8%.
Key Financial Performance
Net Product Sales for 2025 $232 million, an increase of $87 million or 60% compared to 2024. This growth was driven by increased demand across the portfolio, a one-time favorable effect from increased patient affordability, and favorable gross-to-net dynamics, partially offset by lower inventory levels.
Fourth Quarter Net Product Sales $65.4 million, an increase of $18.9 million or 41% compared to the fourth quarter of 2024. This includes TAVALISSE net product sales of $45.6 million (47% increase), GAVRETO net product sales of $10.2 million (27% increase), and REZLIDHIA net product sales of $9.6 million (29% increase).
Total Revenue for Fourth Quarter 2025 $69.8 million, which includes $4.4 million in contract revenues driven by TAVALISSE availability in global markets and other collaborations.
Net Income for Fourth Quarter 2025 $268.1 million compared to $14.3 million for the same period in 2024. This increase was primarily driven by a nonrecurring income tax benefit from the release of the valuation allowance on deferred tax assets.
Net Income for Full Year 2025 $367 million compared to $17.5 million for the full year of 2024. This increase was also driven by the nonrecurring income tax benefit.
Cash Position at End of 2025 $155 million compared to $77.3 million at the end of 2024, reflecting disciplined capital allocation and increased profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
R289: A dual IRAK1/4 inhibitor, currently being evaluated in patients with lower-risk MDS. It offers a novel mechanism to address hyperinflammatory signals in lower-risk MDS and potentially other diseases. Promising Phase Ib study results were presented, showing encouraging safety and preliminary efficacy.
TAVALISSE: Cornerstone product approved for adult chronic ITP treatment. Achieved record quarterly sales of $45.6 million in Q4 2025, a 47% increase year-over-year.
REZLIDHIA: In-licensed in 2022, achieved $9.6 million in Q4 2025 sales, a 29% increase year-over-year. Demonstrates durable responses in IDH1 mutated relapsed/refractory AML.
GAVRETO: Added to the portfolio in 2024, achieved $10.2 million in Q4 2025 sales, a 27% increase year-over-year. Successfully integrated into Rigel's portfolio.
Global Expansion: TAVALISSE is commercially available in Europe, Japan, South Korea, Asia, Canada, and Israel. Partners are pursuing regulatory approvals in new markets.
REZLIDHIA Expansion: Expanded relationship with Kissei for several Asian countries and entered an exclusive license agreement with Dr. Reddy's for additional territories.
Revenue Growth: Achieved $232 million in net product sales in 2025, a 60% increase compared to 2024. Q4 2025 sales reached $65.4 million, a 41% year-over-year growth.
Profitability: Rigel has been profitable since Q3 2024, with a significant increase in cash position by over $100 billion since then.
Financial Guidance: 2026 revenue guidance is $275-$290 million, with $255-$265 million from net product sales and $20-$25 million from contract revenues.
Portfolio Expansion: Focused on in-licensing late-stage assets in hematology and oncology that leverage existing infrastructure. Successfully integrated REZLIDHIA and GAVRETO.
R289 Development: Advancing R289 in lower-risk MDS with plans for a registration study. Exploring additional indications for R289.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Product Development Risks: The company acknowledges that forward-looking statements regarding financial outlook and plans for regulatory and product development are subject to risks and uncertainties, which may cause actual results to differ from forecasts.
Market and Competitive Pressures: The company faces competitive pressures in the hematology and oncology markets, particularly as it seeks to expand its portfolio through in-licensing or acquisition of late-stage assets.
Supply Chain and Inventory Risks: The company experienced lower inventory levels, which partially offset the growth in net product sales, indicating potential supply chain or inventory management challenges.
Economic and Financial Risks: While the company has been profitable since Q3 2024, maintaining financial discipline and managing cash flow remain critical as it pursues growth through acquisitions and clinical development.
Clinical Development and Execution Risks: The success of R289 in lower-risk MDS and other indications is critical to the company's future growth. However, the drug is still in early clinical phases, and its success is uncertain.
Global Market Access Risks: The company is working to expand access to its products in global markets, but regulatory approvals and market penetration in these regions remain uncertain.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Rigel expects total revenue in the range of approximately $275 million to $290 million for 2026, comprised of approximately $255 million to $265 million in net product sales and $20 million to $25 million of contract revenues.
Growth Projections: The company anticipates achieving a compound annual growth rate of approximately 35% since 2022, driven by strong commercial execution and portfolio expansion.
Product Development: Rigel plans to advance R289 in lower-risk MDS and potentially additional indications, with dose expansion phase data expected by the end of 2026. The company is also evaluating additional opportunities for R289 in other indications.
Strategic Plans: Rigel aims to selectively pursue late-stage in-licensing and acquisition opportunities to expand its commercial portfolio, targeting assets that are NDA ready, under review, or commercially available, with launches ideally by 2028.
Market Trends: The company is focused on areas of significant unmet need, particularly in hematology and oncology, and sees large commercial opportunities in these sectors.
Financial Discipline: Rigel plans to maintain financial discipline while delivering another year of top-line growth and positive net income in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the incremental growth drivers for TAVALISSE and the potential growth for GAVRETO?
A:TAVALISSE experienced its largest growth year due to increased affordability from the elimination of the Medicare Part D coverage gap, which was a one-time effect. Future growth will focus on new patient starts, targeting the 14,000-patient market in the second-line and later setting. Efforts include spreading awareness through virtual sales teams. For GAVRETO, the product grew from $28-30 million to over $40 million last year, driven by having it for a full year versus half a year in 2024. Targeted efforts will continue to grow its sales.
Q:What is the company's preference between 500 QD and 500 BID dosing for their drug?
A:The company does not have a preference yet. They are waiting for data to unfold. BID dosing may offer more tonic suppression of inflammation, but both doses were active in the ASH data. The decision will depend on further data.
Q:What is the company's approach to business development (BD) and acquiring new assets?
A:The company is evaluating multiple opportunities in hematology/oncology, focusing on late-stage assets that are NDA-ready, NDA-filed, or already approved. They aim to add value to product launches and hope to accomplish a new acquisition in 2026.
Q:What is the rationale for exploring the post-ESA or treatment-naive MDS population with R289?
A:The company is optimistic about moving R289 into an earlier line of therapy, expecting better activity compared to heavily pretreated patients. They aim to evaluate R289 in less heavily pretreated patients once the recommended Phase II dose is determined, to gather preliminary data.
Q:What is the enrollment status and follow-up requirements for the dose expansion phase of R289?
A:Enrollment is progressing, and the recommended Phase II dose is expected to be selected in the second half of the year. Patients need at least 16 weeks of treatment for evaluation of red cell transfusion independence. The decision will be based on PK, safety, and efficacy data.
Q:Why does the company’s net product sales guidance for 2026 seem conservative?
A:The guidance reflects double-digit growth on top of a strong 2025 performance, which included a one-time favorable effect from improved patient affordability and gross-to-net dynamics. The company does not expect to replicate the 60% growth of 2025 but aims for incremental double-digit growth.
Q:Does the company plan to expand its sales force given the recent revenue growth?
A:No, the company believes its sales force is appropriately sized and focused on the right clinicians. They are leveraging data and innovative tools to target opportunities effectively, rather than expanding the team.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the preference between 500 QD and 500 BID dosing, stating they would wait for data to unfold. Additionally, the response to the business development question was vague, emphasizing ongoing evaluations without specific details or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Benefit income
Executive VP
Ib study
MDS indication
Phase Ib
RBC TI
REZLIDHIA
Slide product
TI week
VP Chief
allowance tax
benefit state
cash generation
cash position
characteristic
dose study
efficacy result
income tax
increase TAVALISSE
integration
mechanism
milligram patient
noncash income
olutasidenib
patient ESAs
patient RBC
portfolio expansion
product portfolio
profitability
release valuation
result Phase
sale year
stage
state tax
tax asset
tax benefit
tax income
tax noncash
treatment adult
valuation allowance
year sale
RIGL Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights strong financial performance with significant year-over-year sales growth across key products, despite a slight net income decline due to higher R&D and operational expenses. The Q&A section reveals management's strategic focus on hematology/oncology, with promising developments for R289. Although some details were unclear, the overall sentiment is positive, supported by a robust revenue increase and strategic product focus. Given the company's small-cap status, the stock is likely to react positively, falling into the 2% to 8% range over the next two weeks.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call indicates strong financial performance with significant revenue and net income growth, a raised revenue guidance for 2025, and strategic product development plans. Despite some uncertainties in global market access and management's vague responses in the Q&A, the overall sentiment is positive due to the raised guidance and strong financial metrics. The market cap suggests a moderate reaction, leading to a predicted stock price movement of 2% to 8%.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlighted strong financial performance with record revenue and net income, a raised revenue guidance for 2025, and significant product sales growth. Despite some uncertainties in product development and strategic collaborations, the market reacted positively to the optimistic guidance and financial discipline. The Q&A revealed management's cautious optimism and focus on strategic growth, without major negative surprises. Given the company's small-cap status, the positive financial results and guidance are likely to drive a stock price increase in the short term.
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call reveals strong financial performance with a 76% increase in net product sales and a significant net income turnaround. The company's strategic partnerships and product demand growth, particularly for GAVRETO, are positive indicators. Despite some risks in strategic execution and global expansion, the optimistic guidance and financial discipline suggest a positive stock price movement. The market cap indicates a potential for notable reaction, but not extreme, leading to a 'Positive' sentiment.
RIGL Slides
RIGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
